Back to Search
Start Over
Human Engineered Heart Muscles Engraft and Survive Long-Term in a Rodent Myocardial Infarction Model
- Source :
- Circulation research, vol 117, iss 8
- Publication Year :
- 2015
-
Abstract
- Rationale: Tissue engineering approaches may improve survival and functional benefits from human embryonic stem cell–derived cardiomyocyte transplantation, thereby potentially preventing dilative remodeling and progression to heart failure. Objective: Assessment of transport stability, long-term survival, structural organization, functional benefits, and teratoma risk of engineered heart muscle (EHM) in a chronic myocardial infarction model. Methods and Results: We constructed EHMs from human embryonic stem cell–derived cardiomyocytes and released them for transatlantic shipping following predefined quality control criteria. Two days of shipment did not lead to adverse effects on cell viability or contractile performance of EHMs (n=3, P =0.83, P =0.87). One month after ischemia/reperfusion injury, EHMs were implanted onto immunocompromised rat hearts to simulate chronic ischemia. Bioluminescence imaging showed stable engraftment with no significant cell loss between week 2 and 12 (n=6, P =0.67), preserving ≤25% of the transplanted cells. Despite high engraftment rates and attenuated disease progression (change in ejection fraction for EHMs, −6.7±1.4% versus control, −10.9±1.5%; n>12; P =0.05), we observed no difference between EHMs containing viable and nonviable human cardiomyocytes in this chronic xenotransplantation model (n>12; P =0.41). Grafted cardiomyocytes showed enhanced sarcomere alignment and increased connexin 43 expression at 220 days after transplantation. No teratomas or tumors were found in any of the animals (n=14) used for long-term monitoring. Conclusions: EHM transplantation led to high engraftment rates, long-term survival, and progressive maturation of human cardiomyocytes. However, cell engraftment was not correlated with functional improvements in this chronic myocardial infarction model. Most importantly, the safety of this approach was demonstrated by the lack of tumor or teratoma formation.
- Subjects :
- Male
Time Factors
Physiology
medicine.medical_treatment
Nude
Myocardial Infarction
030204 cardiovascular system & hematology
Cardiorespiratory Medicine and Haematology
Cardiovascular
Regenerative Medicine
Rats, Sprague-Dawley
0302 clinical medicine
Myocytes, Cardiac
Myocardial infarction
Heart transplantation
cardiac function tests
0303 health sciences
Graft Survival
Cell Differentiation
Papillary Muscles
3. Good health
myocardial ischemia
Heart Disease
Cardiology
Heterografts
Cardiology and Cardiovascular Medicine
Cardiac
Immunosuppressive Agents
medicine.medical_specialty
Cell Survival
Clinical Sciences
Ischemia
Transfection
Article
Cell Line
03 medical and health sciences
Rats, Nude
Internal medicine
medicine
cardiac MRI
Bioluminescence imaging
Animals
Humans
Heart Disease - Coronary Heart Disease
Embryonic Stem Cells
030304 developmental biology
Myocytes
Transplantation
Tissue Engineering
business.industry
Animal
Stroke Volume
medicine.disease
Stem Cell Research
Embryonic stem cell
Myocardial Contraction
Surgery
Rats
Disease Models, Animal
Cardiovascular System & Hematology
Heart failure
Connexin 43
Disease Models
Heart Transplantation
Sprague-Dawley
business
Reperfusion injury
Biomarkers
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Circulation research, vol 117, iss 8
- Accession number :
- edsair.doi.dedup.....206211c764a8126399969ae185192f12